Tag Archives: HEA

PR Newswire

Jim Lim joins Zühlke Group as Head of Health & Medtech in Singapore

Leave a comment

SINGAPORE, April 21, 2023 /PRNewswire/ — Zühlke Group is pleased to announce the appointment of Jim Lim as Head of Market Unit (Health & Medtech) at Zühlke Asia. Based in Singapore, Jim will lead the organisation’s regional efforts to serve the healthcare industry and continue to expand Zühlke’s healthcare expertise and offerings to the ecosystems of healthcare providers, pharmaceutical and medtech companies in Asia.

Jim Lim, Head of Health & Medtech - Zühlke Asia
Jim Lim, Head of Health & Medtech – Zühlke Asia

With over 24 years of ICT industry experience, Jim brings his wealth of experience providing strategic, business and technological advice to global clients. Having held various senior leadership positions across MNCs, Jim has served clients across multiple industry verticals such as healthcare, pharmaceutical, medtech, telecommunications, financial services, education and manufacturing. Jim was also the founding CEO of Good Doctor Technology, a joint venture between Ping An Good Doctor, Grab and Softbank.

Outside his corporate career, Jim is the co-founder of a socio-techno network focused on bringing together the expertise, experiences and connections of senior executives globally to contribute back to society. He is appointed Senior Fellow by the Singapore University of Social Sciences and Executive Education Fellow by the National University of Singapore. He also serves as an industry mentor for Young NTUC and Vice President for Cloud Security Alliance Singapore Chapter.

Driving the future of health innovation through impactful work

Jonas Trindler, CEO Asia, Member of Group Executive Board & Partner of Zühlke Group, commented, “We’re actively contributing to significant breakthroughs in the health markets, with the pandemic accelerating digitalisation across health ecosystems. Together with our clients, we are solving critical challenges in this space to improve healthcare with quality and access. We are confident that Jim’s extensive experience and strategic leadership will enable us to drive further growth and meaningful innovation in the health and medtech space.”

“Asia is paving the way for next-generation digital healthcare and medtech ecosystems. I look forward to leading Zühlke’s health market at such an exciting time and contributing to impactful innovation to transform and provide sustainable healthcare to the everyday lives of people,” commenting on his new role, Jim said.

Zühlke – Empowering Ideas.

Zühlke is a global innovation service provider. We envisage ideas and create new business models for our clients by developing services and products based on new technologies – from the initial vision through development to deployment, production, and operation. We specialise in strategy and business innovation, digital solutions, and application services – in addition to device and systems engineering. Our outstanding solutions provide unique business value and a reliable foundation for sustained success.

Zühlke was founded in Switzerland in 1968 and is owned by its partners. Our 1,900 employees are based in Austria, Bulgaria, Germany, Hong Kong, Portugal, Serbia, Singapore, Switzerland, the United Kingdom and Vietnam, serving clients from a wide range of industries. In addition, our venture capital arm Zühlke Ventures provides start-up financing in the high-tech sector.

Contact: Lorraine Lai, lorraine.lai@zuhlke.com, +6569217800

PR Newswire

uLab® Launches the Orthodontics Industry’s First Suite of Practice-Branded Packaging Options

Leave a comment

MEMPHIS, Tenn., April 19, 2023 /PRNewswire/ — uLab Systems™, the creator of the uSmile™ clear aligner platform and the new uAssist™ concierge service, announces it now offers orthodontists a suite of branding options that give them the ability to create a variety of custom-designed packaging products that will enhance the patient experience and can help grow new business. Since 2021, uLab customers have benefited from the option to package a patient’s aligner in a box designed with the orthodontist’s name and/or logo. Now, the aligner pouch and aligner case can also perform as marketing platforms and will come as a custom-branded package with the box. In addition, orthodontists can now order branded typodonts and patient brochures for their in-office consultations. The new suite of custom options will be available in May.  

An example suite of custom logo items for patient aligner cases manufactured by uLab Systems for Wu Orthodontics.
An example suite of custom logo items for patient aligner cases manufactured by uLab Systems for Wu Orthodontics.

“The ability to brand the aligner package, pouch, and aligner case with our practice logo allowed us to provide the patient with a unique, personalized experience,” says Dr. Kevin Oliviera from Coastal Orthodontics, a member of the pilot group that trialed the customized items. “When a patient is presented with a custom-branded package, it reinforces the value of receiving a high-quality aligner that was designed by someone they know and trust. The patient’s confidence in us and their peace of mind are invaluable,” he adds. Dr. Oliviera also notes that the branded items are giving his/her practice much more visibility in the community. “They are terrific marketing tools that distinguish us from other practices.”

Orthodontists develop long-term relationships over the course of their career with the communities where they practice, even treating several generations of families.  “At uLab, we believe it’s more important that our customers promote their brand rather than the manufacturer’s,” says Amir Abolfathi, chief executive officer and co-founder of uLab.  “It is the orthodontist’s expertise and their patient care that help create beautiful smiles. uLab provides them with the innovative software tools and proven materials they need to develop an effective treatment, but it is ultimately up to them to create the smiles. Their brand and expertise are what patients should associate with quality results.”

uLab is dedicated to innovating for the orthodontic specialty, providing practitioners with easy access to innovative, state-of-the-art tools that enable the flexibility to control the patient treatment plan, unencumbered by pricing structure confines and restrictive protocols. The company has delivered on that commitment since its inception with the release of its in-office aligner design and printing software, uSmile aligners, the uAssist concierge service, and now its custom packaging capabilities. uLab has future plans for “all-digital” platform options, enhanced AI-guided planning tools, and features to enable direct print outputs.

uSmile aligners are manufactured in Memphis, Tennessee, and can be delivered in as few as three business days*. The uLab platform allows orthodontists ultimate control over their aligner treatments. More than 800,000 aligner treatment cases have been planned to date.

* Shipment times may vary depending on location and delivery time selection.

About uLab Systems
uLab Systems is led by an experienced team of healthcare innovators helping to transform options for orthodontic practices to provide the best outcomes for their patients. uLab’s mission is to advance the orthodontic industry with aligner products and digital treatment planning software that let orthodontists take back control of their treatment plans. To learn more visit www.ulabsystems.com. Contact: David Thrower, Chief Commercial Officer, pr@ulabsystems.com

© 2023 uLab Systems, Inc. All Rights Reserved. uLab Systems, uSmile, uAssist, uView, Smart Outcomes, and Smart Office are trademarks and uLab and uDesign are registered trademarks of uLab Systems, Inc. MAR-0001304 Rev 1
Now available! Orthodontists that want to promote their brand for patient aligner cases will now receive custom logo aligner pouches and an aligner case packaged with the custom logo box.
Now available! Orthodontists that want to promote their brand for patient aligner cases will now receive custom logo aligner pouches and an aligner case packaged with the custom logo box.

Photo – https://techent.tv/wp-content/uploads/2023/04/ulab-launches-the-orthodontics-industrys-first-suite-of-practice-branded-packaging-options-2.jpg
Photo – https://techent.tv/wp-content/uploads/2023/04/ulab-launches-the-orthodontics-industrys-first-suite-of-practice-branded-packaging-options.jpg
Logo – https://techent.tv/wp-content/uploads/2023/04/ulab-launches-the-orthodontics-industrys-first-suite-of-practice-branded-packaging-options-1.jpg

Source: uLab Systems, Inc.

PR Newswire

DIGITAL THERAPEUTICS STARTUP RESPIREE™ ANNOUNCES RESIDENCY AT JLABS @ SHANGHAI

Leave a comment

SINGAPORE, April 10, 2023 /PRNewswire/ — Respiree announced today that it has become a resident of Johnson & Johnson Innovation – JLABS @ Shanghai (‘JLABS’)[1] from February 21, 2023 , in order to expand its footprint with the goal of deepening its relationships and networks within the pharma and life science sector.

Respiree’s team at JLABS will focus on utilizing the iRIS One decentralized clinical trials platform with the aim to optimize drug trials and discover newer lung and cardiac digital biomarkers. Respiree’s team also aims to extend development of its novel digital therapeutics pipeline to incorporate real-world pharma evidence.

“We are very proud and excited to be joining the JLABS ecosystem. We hope to enhance the iRIS One clinical trials platform.  Through our expanded connectivity we also hope to further develop our digital therapeutics pipeline with the ultimate aim of enabling patients to access better treatments faster,” said Respiree’s CEO and Founder Dr Gurpreet Singh.

Respiree received the 510(k) clearance for its RS001 Cardio-respiratory wearable from the United States Food and Drug Administration (FDA) on 8 March 2023.

[1] Johnson & Johnson Innovation

About Respiree

Respiree is a digital therapeutics company providing personalized healthcare services for cardio-pulmonary disease management using a combination of proprietary breath-cardio sensors, AI and workflow integrated UIUX. Respiree is deployed internationally. Respiree’s iRIS One clinical trials platform is CE marked, approved for use in Australia by the Therapeutics Goods Administration and just received 510(k) clearance for its RS001 Cardio-respiratory wearable from the United States Food and Drug Administration.

PR Newswire

Picarro Cavity Ring-Down Spectroscopy Successfully Validated Under EPA’s OTM-47 to Measure Ethylene Oxide Emissions in Real-Time from Stationary Sources

Leave a comment

SANTA CLARA, Calif., April 5, 2023 /PRNewswire/ — Picarro, Inc. today announced the successful validation and use of the company’s Cavity Ring-Down Spectroscopy (CRDS) under Other Test Method 47 (OTM-47) as published by the Environmental Protection Agency (EPA) on March 23, 2023. The method describes the measurement of ethylene oxide (EtO or EO) emissions from stationary sources by CRDS. OTM-47 represents the first EtO specific real-time stack test method and will provide the industry with a reliable technique for demonstrating regulatory compliance.

CRDS is a highly sensitive analytical technology that can accurately measure trace levels of EtO emissions from source, stack, and ambient applications. The development of OTM-47 was conducted by third-party stack testing company, CleanAir Engineering, using multiple commercially available Picarro instruments, and through site-specific requests for the use of CRDS in performance testing at commercial sterilization facilities. Data gathered through EPA Method 301 validation of OTM-47 demonstrates that Picarro’s CRDS is a reliable and robust technology that can be used as an alternative to less precise technology-based methods such as optically enhanced Fourier Transform Infrared Spectroscopy (OE-FTIR), Gas Chromatography (GC), and passive techniques.

The successful validation of this method reaffirms Picarro’s ability to deliver accurate and reliable testing solutions to medical device and contract sterilization customers and chemical plants. Many incumbent technologies are complicated, expensive to maintain, and require large amounts of downtime due to frequent maintenance. Picarro CRDS operates by measuring the decay rate of light inside of a robust optical cavity using a coherent light source making its systems less susceptible to interference when measuring target gases such as EtO.

“We are excited to see the successful validation of CRDS under Other Test Method 47. This method will allow customers emitting ethylene oxide to generate more accurate and defensible data than other technologies, which is critical for ensuring compliance and mitigating regulatory risk,” said Joel Avrunin, Vice President of Environmental at Picarro.

About Picarro
Picarro is a leading provider of Cavity Ring-Down Spectroscopy (CRDS)-based, real-time monitoring solutions that offer advanced detection and data analytics technology. Picarro’s suite of systems provides end-to-end visibility with monitoring systems for stacks, indoor air, and fencelines that are supported by a team of experienced and highly qualified professionals who are committed to providing turn-key solutions to customers.  With more than 25 years of expertise and thousands of customers in nearly 100 countries, Picarro is a trusted and reliable partner in ensuring compliance with regulations and environmental standards. For more information, visit www.picarro.com.

Media Contacts:
Jake Thill
Director, Marketing Communications
Picarro, Inc.
jthill@picarro.com

Source: Picarro, Inc.

PR Newswire

Clarivate Announces Gordon Samson as President, Intellectual Property and Nominates Dr. Saurabh Saha as New Independent Director

Leave a comment

Naming the first of three business leaders for its newly created market segments and nominating new Independent Director to its Board

LONDON, March 24, 2023 /PRNewswire/ — Clarivate Plc (NYSE: CLVT), a global leader in connecting people and organizations to intelligence they can trust, today announced that Gordon Samson, currently Chief Product Officer, has been appointed President of its Intellectual Property (IP) market segment, effective April 1. The Company also announced that it has nominated Dr. Saurabh Saha to stand for election as a director at its 2023 Annual General Meeting of shareholders on May 4, 2023.

Jonathan Gear, Chief Executive Officer, Clarivate said: “I’m very pleased to announce the appointment of Gordon who has been a trusted and valued member of our Executive Leadership Team since he came to Clarivate from CPA Global as part of our acquisition in 2020. In this newly created role, he will be responsible for accelerating the growth of our IP segment empowering customers to establish, protect and manage their IP.

Based on my experience working with him over the last eight months and the work we’ve done this year to align the organization, I’m confident that he will be instrumental to how we capitalize on product and service innovation to deliver organic growth. This is the first of our presidential appointments and we look forward to providing updates on further appointments in due course.”

Samson joined Clarivate in October 2020 with the acquisition of CPA Global, having joined CPA Global in 2014 as Chief Operating Officer. During the last three years with Clarivate, Samson has made significant contributions, helping transform the Company’s APAC region and bringing together the Company’s entire product portfolio to offer customers a full range of enriched data, insights, analytics and workflow solutions. He has a long and successful track record of driving organizational transformation and growth in the IP industry and beyond, having held senior executive roles with both operating and P&L accountability for more than 20 years.

Andy Snyder, Chairman of the Board, Clarivate commented: “We look forward to Dr. Saha joining our Board. He will bring a great deal of experience in the pharmaceutical and biotech industries and his guidance will provide valuable insights and perspective, especially as we continue to execute on our growth strategy in the Life Sciences & Healthcare segment.”

Dr. Saha is a physician-scientist, pharmaceutical executive, and biotech entrepreneur dedicated to discovering and developing novel life-changing medicines. He is notable for leading the development and demonstrating human effectiveness of two innovative cancer drugs, an ERK kinase inhibitor (Ulixertinib) and an oncolytic immunotherapy (C. novyi-NT). He is currently CEO of Centessa Pharmaceuticals (NASDAQ: CNTA), a global pharma company. Prior to Centessa, Dr. Saha was a Senior Vice President of R&D and Global Head of Translational Medicine for all disease areas at Bristol Myers Squibb. Other past roles include Venture Partner at Atlas Venture, a VC firm in Cambridge MA, Chief Executive Officer at Delinia, Chief Medical Officer of Synlogic, a management consultant at McKinsey & Company, and head of the New Indications Discovery Unit at Novartis. He is an associate member and Global Clinical Scholar at Harvard Medical School, holds an MD and PhD in medicine and cancer genetics from The Johns Hopkins School of Medicine, an MSc in biophysics from the University of Oxford and a BSc in biochemistry from Caltech.

About Clarivate

Clarivate™ is a leading global information services provider. We connect people and organizations to intelligence they can trust to transform their perspective, their work and our world. Our subscription and technology-based solutions are coupled with deep domain expertise and cover the areas of Academia & Government, Life Sciences & Healthcare and Intellectual Property. For more information, please visit clarivate.com.

Investor Relations Contact
Mark Donohue, Head of Investor Relations, investor.relations@clarivate.com, +1 (215) 243 2202

Media Contact
Amy Bourke-Waite, Senior Director, Corporate Communications, newsroom@clarivate.com

PR Newswire

Martech platform Ortto celebrates record growth on the anniversary of its rebrand

Leave a comment

The unified customer data, analytics, and marketing automation platform Ortto, formerly Autopilot, continues to see double-digit monthly growth a year on from its rebrand. The martech company now has more than 3,000 customers globally and was recognized in 49 categories in G2’s biannual report.

SYDNEY, March 8, 2023 /PRNewswire/ — Ortto, which started as Autopilot Journeys in 2015, rebranded in early 2022 following the launch of a revolutionary new platform that allows marketers to effortlessly connect previously siloed data sources to get a complete view of their customers. Marketers can analyze and operationalize this data without the need for specialized support, enabling them to deliver personalized customer journeys at scale, increasing the impact of their campaigns with powerful event-based triggers and AI-content optimization. In the year since the rebrand, Ortto’s users have built some 5,000 journeys and sent more than 210 million emails to their customers, contributing to the  company’s sustained 16% month-on-month growth.

Ortto helps data-driven marketers easily build powerful reports to understand what’s working and make decisions with confidence. Dashboards allow teams to pin key reports to a shared space so they never lose sight of key metrics.
Ortto helps data-driven marketers easily build powerful reports to understand what’s working and make decisions with confidence. Dashboards allow teams to pin key reports to a shared space so they never lose sight of key metrics.

  • The powerful platform received the ‘High Performer’ badge in 11 categories in the G2 Winter 2023 reports, including marketing automation and marketing platform, across multiple regions (APAC, ANZ, Europe, UK, etc.)
  • Ortto was also awarded the ‘Best estimated ROI’ badge and the ‘Easiest to use’ badge in the customer journey mapping categories, as well as the ‘Users Love Us’ badge.
  • The platform was also ranked number one for data personalization by SoftwareReviews.

Customer, Mica Shtewi, Tech Manager at Pattern, comments:

“When you’re moving into a world we’re moving into, you have so many data sources that you’re trying to bring together and various communications to get clients moving through the sales process. We needed something flexible that works and had a robust integration with Salesforce, and with Ortto we can target people the way we want to target them.”

Visually design journeys that automate personalized messages and trigger actions across the customer lifecycle with Ortto.
Visually design journeys that automate personalized messages and trigger actions across the customer lifecycle with Ortto.

Michael Sharkey, CEO and co-founder of Ortto, comments:

“Everyone recognizes the importance of data in building better, more personalized customer experiences, but the problem is, for many businesses, this data is located across a number of different tools and isn’t easily accessible to marketers. That’s why we rebuilt our platform to make it easy to bring all of that data together in one place and remove the barriers to entry, so marketers have ready access to the data they need without having to lodge a ticket or learn SQL. The response to the new platform has been incredible – not only from our Autopilot customers, who are realizing new value through Ortto, but also from new customers who have come on board in the past year.”

About Ortto

Ortto, the world’s first complete marketing automation, AI and analytics platform, empowers marketers to act with confidence and increase their impact on revenue. By combining three powerful tools into one intuitive platform, teams finally benefit from their customer data, messaging, and analytics working together.

Sophisticated yet easy to use, more than 3,000 customers trust Ortto to understand their impact, discover their next marketing opportunity, and continuously iterate to deliver great customer experiences at scale. Learn more at: www.ortto.com 

Launched in 2015, Ortto’s team is located in Australia, Europe and the US. To date, the company has raised $35M in venture funding from backers including Blackbird, Rembrandt and Salesforce Ventures.

Source: Ortto, Inc.

PR Newswire

US proteomics sector set for shake-up as new IonOpticks tech unveiled

Leave a comment

IonOpticks to introduce the TS, a fully integrated column heating and interface solution for Thermo Scientific users

MELBOURNE, Australia, March 3, 2023 /PRNewswire/ — IonOpticks, a producer of high-performance chromatography solutions for the global research community, will introduce the new TS product range to the US market at US HUPO’s (US Human Proteome Organization) 19th Annual Conference in Chicago on 4-8th March, a renowned event attended by proteomics experts from around the globe.

IonOpticks’ new TS range was developed as a simple plug-and-play, fully integrated heating and source solution for Thermo Scientific mass spectrometer users, who have previously only been able to access the results achievable with IonOpticks Aurora Series columns by creating their own interface – a costly and difficult alternative.

“Researchers can now easily unlock the full potential of their mass specs through the launch of our new TS range. Thermo Orbitraps have been cited in roughly 85% of all publications related to proteomics in the last decade, so we’re excited to make our famed Aurora Series products easily accessible to this significant portion of the mass spec community,” says Xavier Perronnet, Managing Director at IonOpticks.

“We’re excited to be attending US HUPO, to meet with our peers and showcase how the TS, combined with our Aurora Series columns, can provide Thermo mass spec users the ability to supercharge the sensitivity of their existing instruments. Our columns enable researchers to delve deeper into their samples than ever before.” Mr Perronnet continues.

The combination of IonOpticks’ proprietary nanoZero® fittings and integrated emitter with the new TS range removes all pre- and post-column dead volume, maximizing the capacity of the chromatographic packed bed to separate samples. Further, the heating solution in the TS is reusable which saves users both time and money while reducing unnecessary waste.

The TS range was developed following the paradigm-shifting release of the Aurora Frontier – the first ever column to routinely generate over 10,000 protein identifications on a Thermo mass spectrometer – from a single sample and single species.

“The results that have been achieved with our Aurora Frontier have been outstanding and we’re proud to continue to develop products that enable us to ensure access to these gains is equal for all researchers,” says Dr Jarrod Sandow, Head of Product Development at IonOpticks.

“Thermo users continue to be top customers of our products, so we’ve worked hard behind the scenes to ensure these users can easily boost the performance of their existing instruments through a simple all-in-one heating and source integration system. One that requires no complex installation and is ready to use straight out of the box,” Dr Sandow adds.

IonOpticks is committed to ensuring the world’s best chromatography is available to all mass spec users. Alongside the TS, IonOpticks have also launched the SX, a fully integrated column heating and interface solution for SCIEX users.

About IonOpticks

IonOpticks produces high-performance chromatography solutions for the global research community.

We specialise in the development and manufacture of columns for analytical applications in liquid chromatography with mass spectrometry (LC-MS) and high-end proteomics. Our highly reproducible methods provide a unique ability to enhance the sensitivity of mass spectrometry sample analysis, enabling scientists and clinicians to discover more from their samples.

Our team are experts in a broad array of LC-MS platform technologies and are driven by the need to improve chromatographic performance in order to achieve data quality and deep proteome coverage on a whole new scale.

https://ionopticks.com/ / https://www.proteomicssolved.com/

Cision View original content:https://www.prnewswire.com/news-releases/us-proteomics-sector-set-for-shake-up-as-new-ionopticks-tech-unveiled-301760866.html

PR Newswire

CGTN: Reflecting on China’s Three-year COVID Battle in Through the Storm

Leave a comment

BEIJING, Feb. 10, 2023 /PRNewswire/ — Since early 2020, China has been following a unique path in combatting COVID-19. Through the Storm condenses this three-year battle into a 60-minute documentary.

This CGTN presentation has its global premiere on February 10. Through the Storm features first-hand accounts of the initial outbreak in Wuhan, the mass vaccination campaign, the Shanghai lockdown and, finally, the reopening and recovery.

Through the Storm answers three essential questions: What was China’s reasoning behind choosing its unique approach to fighting COVID? What actions did China take in the three-year period between its victory in Wuhan and its re-opening? And can China achieve a solid recovery in 2023?

Through the eyes of frontline intensive care specialists, village doctors, community workers, volunteers and decision makers, the documentary reveals the answers.

Reflecting on China’s Three-year COVID Battle in Through the Storm
Reflecting on China’s Three-year COVID Battle in Through the Storm

THE WINDOWS OF OPPORTUNITIES

What China faced in early 2020 was the original strain of the novel coronavirus, which was far more virulent and deadly than the current Omicron strain. At the time, there were just 63,000 ICU beds for a population of 1.4 billion. Even China’s finest medical minds seemed helpless in the face of this unknown enemy.

The dire situation faced by Wuhan could have been repeated all across the country. But thanks to China’s rigorous COVID policies, a national disaster was averted.

Nearly 120,000 ICU beds have been added since the start of the outbreak. As a result, China now has more ICU beds per 100,000 people than developed countries such as Britain, Japan, Spain and France. Also, the country’s medical staff have accumulated experience and skill in dealing with the Omicron strain, adopting a series of updated treatment protocols and diagnostic techniques. In the course of two years, China vaccinated over 91% of its population, with special emphasis on the elderly.

THE BARRIERS

In the three years that followed the initial outbreak, much has changed. From stringent community lockdowns, mass PCR testing and the setting up of makeshift hospitals, the experience gained and measures adopted in Wuhan were embraced and perfected.

Since January 10, 2020, there have been a total of 250 days when no new COVID cases were reported. Zhong Nanshan, China’s leading expert on respiratory diseases, estimates that over 20 million lives have been saved, as a result of China’s stringent anti-COVID policies.

The Chinese people were always confident that they could defeat the virus.

Following the Alpha, Delta and Gamma variants came the Omicron strain, which infects the human body 70 times faster, but with symptoms that are far less severe.

The evolving variants brought greater challenges. In response, China regularly adjusted its prevention and control measures, until eventually the decision was taken to make a major shift in its COVID policies at the end of 2022.

BACK ON COURSE

Throughout the pandemic, China remained a major contributor to global economic growth. Over the past five years, in spite of the global instability, the pandemic and a domestic slowdown, China has still managed to achieve average annual GDP growth of 5%.

A major beneficiary of the easing of the anti-COVID measures has been the movie industry. Box-office receipts during the seven-day Spring Festival holiday were the second-highest ever on record, at one billion US dollars. During the same period, over 300 million passenger journeys were recorded on the country’s transport network, generating revenue of 56 billion US dollars for the tourism industry, a 30% year-on-year increase.

The IMF raised the estimate for China’s 2023 GDP growth from 4.4% to 5.2%. Morgan Stanley is even more optimistic, improving its growth outlook to 5.7% in a research note released in January, 0.3 percentage point higher than its previous estimate.

Although the world is now gradually recovering from the pandemic, the novel coronavirus is still present. To secure a more certain future for humankind, greater, more effective and broader global cooperation is essential.

PR Newswire

Guardant Health to integrate Lunit’s AI-based scoring algorithm for PD-L1 into its portfolio to enhance cancer biomarker detection

Leave a comment

  • Powered by Lunit SCOPE PD-L1, the Guardant360 TissueNext PD-L1 test with Guardant Galaxy™ shows improved detection of the biomarker in NSCLC
  • Lunit’s AI solution is the first application in Guardant Galaxy, a suite of AI and other technology tools that enhance Guardant Health’s portfolio of cancer tests

SEOUL, South Korea, Jan. 31, 2023 /PRNewswire/ — Lunit (KRX:328130.KQ), in partnership with leading precision oncology company Guardant Health, today announced the integration of its AI-based PD-L1 scoring algorithm into Guardant’s testing workflow to enhance biomarker detection in the Guardant360 TissueNextTM PD-L1 test for non-small cell lung cancer (NSCLC).

The newly integrated algorithm will enable Guardant to offer augmented biomarker assessment for NSCLC patients through AI-based quantification of tissue samples using a scoring system generated by Lunit SCOPE PD-L1. The enhanced Guardant test is designed to support pathologists in diagnosing PD-L1 status with higher accuracy and efficiency. Through the AI software, the test showed improved detection of PD-L1 by more than 20 percent compared to manual pathologist interpretation in the most challenging cases in NSCLC1.

Lunit SCOPE PD-L1 is a CE-marked AI solution for detecting and analyzing PD-L1, a cancer biomarker. The solution may assist pathologists by minimizing interpretation discrepancy and allowing better prediction of treatment outcomes for non-small cell lung cancer (NSCLC) patients, as demonstrated in study findings published in the European Journal of Cancer.

Lunit SCOPE PD-L1’s integration with the Guardant360 TissueNext PD-L1 test is the first application in Guardant Galaxy, Guardant Health’s suite of technology applications developed internally and through outside partnerships to enhance the performance and utility of its portfolio of cancer tests.

The two companies have been in partnership since 2021, following a strategic investment from Guardant Health to Lunit.

“We are honored to partner with Guardant Health in leveraging the power of AI and digital pathology to enhance the capabilities of their comprehensive genomic profiling tests for cancer patients,” said Brandon Suh, CEO of Lunit. “The development of the AI-supported scoring algorithm for the Guardant360 TissueNext PD-L1 test is a great example of using advanced medical image analytics to enhance precision diagnostics in lung cancer and help doctors find the right treatment for the right patients.”

“With Guardant Galaxy, we are now accessing the most advanced AI techniques and the latest complementary technologies from leading companies in cancer diagnostics to enhance the capabilities of our tests and provide oncologists and researchers with precise and actionable information,” said Helmy Eltoukhy, co-CEO of Guardant Health. “The digital pathology solution from Lunit has already demonstrated the power of AI to help improve detection of PD-L1 in certain cases of non-small cell lung cancer. We believe it has the potential to contribute much more broadly to advances in identifying cancer biomarkers and informing treatment decisions.”

About Lunit

With AI, Lunit aims to ‘conquer cancer,’ one of the leading causes of death worldwide. Lunit is an AI software company devoted to developing AI solutions for precision diagnostics and therapeutics, to find the right diagnosis at the right cost, and the right treatment for the right patients. Lunit, a portmanteau of ‘learning unit,’ is a deep learning-based medical AI company devoted to developing advanced medical image analytics and data-driven imaging biomarkers via cutting-edge technology.

Founded in 2013, Lunit has been acknowledged around the world for its advanced, state-of-the-art technology and its application in medical images. Its technology has been recognized at international AI competitions surpassing top companies like Google, IBM, and Microsoft. As a medical AI company with a focus on clinical evidence, the company’s findings are presented in major peer-reviewed journals such as the Journal of Clinical Oncology and JAMA Network Open, and global conferences including ASCO and AACR. After receiving FDA clearance and the CE Mark, Lunit INSIGHT CXR and MMG are clinically used in approximately 1,000 hospitals and medical institutions across more than 40 countries. Lunit is headquartered in Seoul, South Korea with offices and representatives around the world.

The tests described have been developed and their performance characteristics determined by the CLIA-certified laboratory performing the test. Lunit SCOPE PD-L1 is CE marked in Europe and has not been cleared or approved by the US Food and Drug Administration (FDA). Although FDA is exercising enforcement discretion of premarket review and other regulations for laboratory-developed tests in the US, certification of the laboratory is required under CLIA to ensure the quality and validity of the tests.

About Guardant Health

Guardant Health is a leading precision oncology company focused on helping conquer cancer globally through use of its proprietary tests, vast data sets and advanced analytics. The Guardant Health oncology platform leverages capabilities to drive commercial adoption, improve patient clinical outcomes and lower healthcare costs across all stages of the cancer care continuum. Guardant Health has commercially launched Guardant360®, Guardant360 CDx, Guardant360 TissueNext™, Guardant360 Response™, and GuardantNFINITY® tests for advanced stage cancer, and Guardant Reveal™ for early-stage cancer. The Guardant Health screening portfolio, including the ShieldTM test, aims to address the needs of individuals eligible for cancer screening.

References

1. Sangjoon Choi et al. Artificial intelligence–powered programmed death ligand 1 analyser reduces interobserver variation in tumour proportion score for non–small cell lung cancer with better prediction of immunotherapy response, European Journal of Cancer 2022, Volume 170, 17-26

Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/guardant-health-to-integrate-lunits-ai-based-scoring-algorithm-for-pd-l1-into-its-portfolio-to-enhance-cancer-biomarker-detection-301734438.html

PR Newswire

Correction – Health in Transportation Releases New Smartphone Face-Scanning Application Aimed at Uncovering Potentially Serious Health Concerns in Professional Drivers

Leave a comment

Correction Notice

Please note the following corrections to the Press Release issued Jan 17, 2023:

  • The CDL Health Scanner is a product of Health in Transportation. NuraLogix does not hold any liability for any applications distributed under the Health in Transportation name.
  • NuraLogix technology, service and products do not uncover, nor identify life-threatening health conditions. NuraLogix technology, service and products are intended to improve your awareness of general wellness and health.
  • Note that NuraLogix technology, service and products are For Investigational Use Only within the USA. NuraLogix technology, service and products are not a substitute for the clinical judgment of a health care professional. NuraLogix technology, service and products are not intended to diagnose, treat, mitigate or prevent any disease, symptom, disorder or abnormal physical state. Always consult with a health care professional or emergency services if you believe you may have a medical issue.
  • NuraLogix is not responsible for any third-party products that may integrate NuraLogix technology, service or products. NuraLogix does not make any claims about, nor have they evaluated the claims of any third-party products using NuraLogix technology, service or products.
  • NuraLogix technology, service and products do not predict the risk of, nor do they provide Obstructive Sleep Apnea (OSA) measurements in any way. NuraLogix technology, service and products do not provide customized health coaching from Medwell, nor sleep-apnea solutions by Dedicated Sleep. NuraLogix technology, service and products do not provide health education, or resources to assist with lifestyle changes.

Corrected Press Release

Please note the following corrected press release. A previous release sent on January 17 contained incorrect or outdated information.

ST. GEORGE, Utah, Jan. 26, 2023 /PRNewswire/ — Health in Transportation, a health and wellness solution provider for the transportation industry, released a revolutionary preventative health tool for drivers called CDL Health Scanner.

Accessed through a specific URL on a smartphone, CDL Health Scanner’s proprietary technology uses a smartphone camera to scan an individual’s face and analyze key vital signs. This unique, driver-centric system uses revolutionary technology from NuraLogix, called Transdermal Optical Imaging (TOI)™, in which a conventional video camera is used to extract blood flow information from the face. Risk factors for hypertension, type-2 diabetes and more are revealed to the individual user on an easy-to-interpret results page.

“It’s an exciting day for the transportation industry,” said Bob Perry, president of Health in Transportation. “For less than the cost of a couple coffee drinks, this new smartphone app will provide health information to drivers, potentially salvaging thousands of driving careers. Our partnership with NuraLogix is dedicated to bringing innovative solutions to directly impact the driver shortage and help keep America’s professional drivers on the road instead of being sidelined due to bad health.”

This new, confidential CDL Health Scanner was developed specifically to protect drivers. With the transportation industry experiencing a shortage of close to 80,000 drivers each year– along with the fact that putting a new driver behind the wheel often involves a five-figure expense for the carrier–thousands of skilled drivers are disqualified from driving each month due to poor health outcomes.

CDL Health Scanner not only alerts drivers of potentially serious health concerns, but it also provides health education focused on the driver and guides them toward resources that can assist with lifestyle changes. Often, drivers are completely unaware of some of these underlying medical conditions, and CDL Health Scanner aims to bring awareness to these important metrics. The app provides support for drivers who may be at risk by providing them with the nearest location of one of the six thousand Higi health check stations.

CDL Health Scanner can be purchased by visiting www.cdlhealthscanner.com.

About Health in Transportation
Health in Transportation (HIT) provides innovative and practical health and wellness solutions for professional drivers in trucking and mass transit. For almost forty years, their programs have helped thousands of drivers avoid medical disqualification with unique coaching mechanisms that drivers can utilize even while they are on the road. Known as ‘The Trucker Trainer’ by professional drivers nationwide, Bob Perry, president of HIT, brings a very distinctive perspective to the issue of a driver’s health and life expectancy. He comes from a family of professional drivers and has spent decades working on driver health initiatives.

About NuraLogix
NuraLogix are the Toronto-based pioneers of the world’s first contactless blood pressure and vital sign measurement solution. NuraLogix uses its patented Transdermal Optical Imaging (TOI™) technology in which a conventional video camera is used to extract facial blood flow information. This technology is the evolution of extensive peer-reviewed research and clinical studies, differentiating NuraLogix from their competitors. NuraLogix has conducted multiple clinical studies and published several research papers in notable scientific publications such as Frontiers in Psychology, Scientific Reports, and the Journal of Natural Sciences (JNS). To date the company has been issued 13 US patents with additional patents pending. Visit their website at www.nuralogix.ai.

For inquiries related to Anura™ and NuraLogix technology, service and products please contact Chris Lin, Chief Marketing Officer, ChrisLin@nuralogix.ai; For inquiries related to CDL Health Scanner and products and services provided by Health in Transportation, please contact Bob Perry, President of Health in Transportation,  bob@healthintransportation.com